In a recent study posted to the medRxiv* preprint server, researchers determined evidence for post-exposure vaccination in reducing the mortality rate of coronavirus disease 2019 (COVID-19).

Postexposure prophylaxis with nirmatrelvir-ritonavir for five or 10 days does not reduce the risk for symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to a ...

In a study conducted at the University of Washington, USA, the researchers assert that post-exposure prophylaxis with monoclonal antibodies could improve the clinical outcomes and health system costs ...

REGEN-COV consists of 2 potent, virus-neutralizing antibodies that bind noncompetitively to the receptor binding domain of the SARS-CoV-2 spike protein. The Food and Drug Administration (FDA) has ...

Human immunodeficiency virus (HIV) post-exposure prophylaxis (PEP) entails the prompt administration of antiretroviral agents following potential exposure to prevent viral acquisition. Clinical ...

Heavy is the head that wears the COVID-19 crown. Late last week, Pfizer revealed its antiviral Paxlovid fell short in a post-exposure protection trial. Still, in the pill’s quest to reach as many ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Following the June update that allowed for a lower dose ...

(RTTNews) - Swiss drug maker Roche Group (RHHBY) announced Tuesday that the U.S. Food and Drug Administration has approved a supplemental New Drug Application or sNDA for Xofluza (baloxavir marboxil) ...